Highlights QuidelOrtho Corporation

Equities

QDEL

US2197981051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 20:00:00 12/03/2026 GMT			5-day change	1st Jan Change
17.92 ^USD	-0.55%		-16.30%	-37.25%

02-16	QuidelOrtho Corporation Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio	CI
02-13	Joseph M. Busky to Retire as Principal Financial Officer of Quidelortho Corporation, Effective as of June 30, 2026	CI

Highlights

02-16	QuidelOrtho Corporation Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio	CI
02-11	QuidelOrtho Q4 Earnings Fall, Revenue Rises; Issues Guidance	MT
02-11	Earnings Flash (QDEL) QuidelOrtho Corporation Reports Q4 Revenue $723.6M, vs. FactSet Est of $700.7M	MT
02-11	Earnings Flash (QDEL) QuidelOrtho Corporation Posts Q4 Adjusted EPS $0.46 per Share, vs. FactSet Est of $0.42	MT
02-11	QuidelOrtho Corporation Provides Earnings Guidance for the Fiscal Year 2026	CI
02-11	QuidelOrtho Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2025	CI
11-05	In vitro diagnostics firm QuidelOrtho beats Q3 revenue expectations	RE
11-05	Earnings Flash (QDEL) QuidelOrtho Corporation Reports Q3 Revenue $699.9M, vs. FactSet Est of $664.9M	MT
11-05	Earnings Flash (QDEL) QuidelOrtho Corporation Posts Q3 Adjusted EPS $0.80 per Share, vs. FactSet Est of $0.46	MT
11-05	QuidelOrtho Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 28, 2025	CI
11-05	Quidelortho Corporation Provides Earnings Guidance for Full Year 2025	CI
11-03	QuidelOrtho Receives FDA 510(k) Clearance for VITROS?? Immunodiagnostic Products hs Troponin I Assay	CI
11-03	Quidelortho receives FDA 510(k) clearance for VITROS Immunodiagnostic Products hs Troponin I assay	RE
22/09/25	QuidelOrtho Corporation Announces Availability of QuICKVUE Influenza + SARS Test for Professional Use	CI
19/08/25	QuidelOrtho Corporation Appoints Erich Wolff as Executive Vice President, Strategy & Corporate Development	CI
13/08/25	QuidelOrtho Corporation Launches Certified Analyzer Program to Enhance Diagnostic Testing Access in Rural Hospitals	CI
06/08/25	QuidelOrtho Fiscal Q2 Swings to Adjusted Earnings, Revenue Falls	MT
05/08/25	QuidelOrtho Q2 revenue falls but beats expectations	RE
05/08/25	Earnings Flash (QDEL) QuidelOrtho Corporation Posts Q2 Adjusted EPS $0.12 per Share, vs. FactSet Est of $0.00	MT
05/08/25	Earnings Flash (QDEL) QuidelOrtho Corporation Reports Q2 Revenue $613.9M, vs. FactSet Est of $611.1M	MT
05/08/25	QuidelOrtho Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 29, 2025	CI
05/08/25	Quidelortho Corporation Reiterates Earnings Guidance for Full Year 2025	CI
14/07/25	QuidelOrtho Corporation and Buildman Laboratories AG Announces Availability of the BuHLMANN FCAL Turbidimetric Immunoassays on Vitroal Pancreatic Elastase	CI
03/06/25	QuidelOrtho Plans to Acquire LEX Diagnostics for $100 Million, Discontinue Savanna Platform	MT
02/06/25	QuidelOrtho Corporation intent to acquire remanining majority stake in Lex Diagnostics Limited from TTP Group plc for approximately $100 million.	CI